Key genetic drivers, including mutations in NF2, SMO, KLF4, TRAF7, and chromosomal aberrations, allow for the stratification of meningiomas into distinct molecular subtypes, each associated with unique clinical outcomes and therapeutic vulnerabilities [4,30,33,34,35,36]. This evidence concerns the gene SMO and meningioma.